United States of America
Over the last two decades, Sun Pharma has established itself as a leading player in the generics market in the U.S. We are the 8th largest generics pharmaceutical company in the U.S. and are ranked 2nd by prescriptions in the U.S. dermatology market. We are rapidly ramping up our presence in the specialty branded market, with dermatology, ophthalmology and oncology as key target segments. Our U.S. business makes up 30% of our global revenue.
Our U.S. headquarters is in Princeton, New Jersey, with distribution, manufacturing and R&D teams at multiple locations across the country.
Contact
Customer Service
If you have any questions about Sun Pharma Products, please contact Sun Pharma Customer Service at 800-818-4555.
If you have any questions about Ranbaxy OTC products, please contact Ranbaxy OTC Customer Service at 1-877-OHM-LABS.
If you have any questions about Sun Pharma Products or Ranbaxy Prescription Products, please contact Sun Pharma Customer Service at 800-818-4555.
Adverse Event Reporting
For reporting adverse drug events (ADEs) related to Sun Pharma products, please contact 1-800-818-4555 and choose Option 3.
For reporting adverse drug events (ADEs) related to Ranbaxy products, please contact 1-800-406-7984.
Medical Information
For information related to a Sun Product marketed in the United States, please call 1-833-SUN-INFO (833-786-4636)
Our Medical Information Specialists are available 8:00AM-8:00PM ET; Monday to Friday except holidays.
Connect with us
Sun Pharmaceutical Industries Inc.,
2 Independence Way,
Princeton,
NJ 08540
(609)720-9200
(609)514-1155
DUSA Pharmaceuticals, Inc.,
25 Upton Drive
Wilmington,
MA 01887
(978) 657-7500
(978) 657-9193
Pharmalucence, Inc.,
29 Dunham Road
Billerica,
MA 01821
Sun Pharmaceutical Industries Inc.,
1 Commerce Drive,
Cranbury,
NJ 08512
(609) 819-8200
(609) 655-7448
Sun Pharma offers a program for individuals who want to disclose violations of US FDA requirements related to facilities or products owned or operated by Ranbaxy prior to Sun Pharma acquisition of Ranbaxy. Continue
Whistle Blower Policy for Sun Pharmaceutical Industries Limited & its Subsidiaries
As a Company of repute and global standing, Sun Pharma is committed to conducting its business by adopting the highest standards of professional integrity and ethical behavior. The organization has a detailed Code of Conduct that directs the Employees to uphold the Company values and urges them to conduct business worldwide with integrity and highest ethical standards. The Company intends to prevent the occurrence of any practice not in compliance with this Code through the Whistle Blower Policy. This mechanism aims to provide a secure environment to Employees for responsible reporting of the Code violations by Employees. please proceed by clicking Continue
Ranbaxy's Disclosure Program
Sun Pharma offers a program for individuals who want to disclose violations of US FDA requirements related to facilities owned or operated by Ranbaxy or products owned by Ranbaxy prior to Sun Pharma’s acquisition of Ranbaxy. This Disclosure Program (the “Ranbaxy Disclosure Program”) applies specifically to those facilities and products, and is different from the Disclosure Programs or policies that apply to other products or facilities owned or operated by Sun Pharma (links to Sun Pharma’s Whistleblower Policy appear in the box above). If you are an individual seeking to disclose issues or questions under the Ranbaxy Disclosure Program, please proceed by clicking Continue
Ranbaxy's Disclosure Policy
Sun Pharma offers a program for individuals who want to disclose violations of US FDA requirements related to facilities owned or operated by Ranbaxy or products owned by Ranbaxy prior to Sun Pharma’s acquisition of Ranbaxy. This Disclosure Program (the “Ranbaxy Disclosure Program”) applies specifically to those facilities and products, and is different from the Disclosure Programs or policies that apply to other products or facilities owned or operated by Sun Pharma (links to Sun Pharma’s Whistleblower Policy appear in the box above). If you are an individual seeking to disclose issues or questions under the Ranbaxy Disclosure Program, please proceed by clicking Continue